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ABSTRACT
Myelodysplastic syndromes (MDS) are clonal disorders of the multipotent hematopoietic stem cell char-
acterized by ineffective hematopoiesis and associated with marrow hypercellularity, increased
intramedullary cell death and peripheral cytopenias of varying severity. Patients with myelodysplasia have
a propensity (20% to 30% of cases) to undergo transformation into acute myeloid leukemia (AML), and a
large body of evidence indicates that MDS represent steps in the multiphasic evolution of AML.
Progression of the disease is characterized by expansion of the abnormal clone and inhibition of normal
hematopoiesis leading to deterioration of the blood cell count and/or development of AML. MDS are rela-
tively unusual in childhood, representing only 3% of pediatric hematological malignancies, although it has
been reported that up to 17% of pediatric AML cases may have a previous myelodysplastic phase. The first
systematic attempt at morphological classification of MDS was provided by the French-American-British
(FAB) group. However, the FAB classification of MDS is only partially applicable in children. Some variants
are extremely rare or absent (refractory anemia with ring sideroblasts and chronic myelomonocytic
leukemia), and other peculiar pediatric disorders, represented by juvenile chronic myelogenous leukemia
(JCML) and the monosomy 7 syndrome, are not included. Moreover, since there is a partial overlap
between pediatric MDS and myeloproliferative disorders and the variants occurring in young children have
rather specific features, some confusion still surrounds the nosographical definition of childhood MDS, so
that none of the proposed classifications are widely accepted and used. Characteristically, some genetic
conditions such as Fanconi’s anemia, Shwachman’s and Down’s syndromes predispose to the development
of MDS in childhood. The most common variants of childhood MDS are represented by JCML and the
monosomy 7 syndrome, both disorders typically occurring in young children. JCML is characterized by a
spontaneous growth of granulocyte-macrophage progenitors that show a striking hypersensitivity to gran-
ulocyte-macrophage colony-stimulating factor. Clinical presentation resembles that of some myeloprolif-
erative disorders, with massive organomegaly usually not observed in the classically reported variants of
MDS. Clinical features of the monosomy 7 syndrome resemble those observed in JCML and a differential
diagnosis between these two entities relies upon the higher percentage of fetal hemoglobin, the more pro-
nounced decrease in platelet count and, in some cases, the lack of the peculiar cytogenetic abnormality in
the latter. With the number of children being cured of cancer constantly rising, a significant increase in sec-
ondary or chemotherapy-related myelodysplasia is being observed, and these disorders represent a formi-
dable challenge for pediatric hematologists due to their poor response to chemotherapy. As a matter of fact,
owing to their biological heterogeneity and aggressive clinical course in childhood, all MDS variants pose
serious difficulties for successful management. If a compatible donor is available, allogeneic bone marrow
transplantation (BMT) becomes the treatment of choice and should be performed during the early stages of
the disease. Supportive therapy, differentiative treatments and low-dose chemotherapy, while valuable
alternative therapeutic options in adults, have limited application in pediatric patients. The role of inten-
sive chemotherapy and autologous BMT has not yet been clearly defined, and the use of hematopoietic
growth factors does not seem to have a significant influence on the natural history of the disease. In the
future, new insights into the events leading to progressive genetic changes in the clonal population and into
the molecular basis of these genetic lesions could result in interesting new therapeutic approaches directed
either at the oncogenes involved in the pathogenesis of the disease, or at the cytokines and/or their recep-
tors causing the abnormal differentiation and proliferation of the myelodysplastic clone.
Key words: myelodysplastic syndromes, bone marrow transplantation, monosomy 7, juvenile chronic myelogenous
leukemia, oncogenes
M
yelodysplastic syndromes (MDS) are a
heterogeneous group of clonal disor-
ders involving the multipotent or
pluripotent hemopoietic stem cell and are usual-
ly characterized by ineffective hematopoiesis
with increased intramedullary cell death that
determines peripheral blood cytopenia.1 - 3
Infection or bleeding due to marrow failure and
a propensity (20% to 30% of cases) to undergo
transformation into acute myeloid leukemia
(AML) represent the main cause of death for
these patients. In fact, a large body of evidence
indicates that MDS represent steps in the multi-
phasic evolution of AML.4,5 Studies of clonality
have shown a variable pattern of clonal prolifer-
ation in MDS: most of the patients studied
demonstrated clonality limited to the granulo-
cytic-monocytic series, but some possessed clon-
al pluripotent progenitors capable of both
myeloid and lymphoid differentiation.4 This het-
erogeneity has also been observed in AML, thus
supporting the preleukemic nature of MDS. In
addition, patients with MDS have been found to
carry the same molecular lesions observed in
AML, in particular point mutations in cellular
proto-oncogenes or genes relevant for cell prolif-
eration and cell death (i.e. RAS genes, c-fms, p53
suppressor gene).4 Different combinations of
these molecular lesions probably explain the
variable clinical course of these patients.2,5
MDS are typical disorders of the elderly, the
reported median age at presentation being 60-
65 years. Even though the precise frequency in
pediatrics is still unclear, Blank and Lange sug-
gested that up to 17% of pediatric AML cases
have a preleukemic phase, and MDS seem to
account for about 2-3% of childhood hemato-
logical malignancies.6 MDS can be primary or
develop following exposure to myelotoxic
agents.7 The incidence of MDS appears to be
increasing with the use of intensive chemo-
radiotherapy, which, though curing the majori-
ty of pediatric patients with cancer, may cause
secondary or therapy-related MDS.8 An increas-
ing number of secondary AML and MDS, most
frequently in children previously treated for
Hodgkin disease but also after other hemato-
logical and non-hematological malignancies,
have recently been reported.9-11
Our knowledge of the pathophysiological
mechanism of MDS has improved considerably
in recent years. Studies of G-6PD polymor-
phism in heterozygous females,12 DNA polymor-
phisms at X-linked loci,13 as well as cytogenetic
analysis of bone marrow (BM) progenitor cells14
have made it clear that these disorders result
from clonal expansion of a multipotent or pluri-
potent hemopoietic progenitor. Mounting evi-
dence indicates that at least two steps are
involved in the pathogenesis of MDS: an early
step that leads to expansion of a genetically
unstable stem cell clone and a later one, often
characterized by the acquisition of chromosome
aberrations, conferring some selective growth
advantage.15 Factors including host susceptibility
related to specific hereditary factors, age and
exposure to leukemogenic agents (benzene,
alkylating drugs and radiation)16 seem to play a
major role in the early event by causing somatic
mutations of growth regulatory genes, such as
RAS genes and c-fms.17-19 However, activation of
individual proto-oncogenes appears to be insuf-
ficient for conferring a malignant phenotype
and at this stage the disease is often clinically
silent. Additional events, namely chromosome
abnormalities, reflecting the genetic instability
of the affected clone, are necessary mediators of
the neoplastic change.4 As mentioned above, dif-
ferent combinations of molecular lesions may
also explain the variable clinical course and bio-
logical behavior of the disease in patients with
identical MDS variants.3,20
Classification of MDS in childhood
Due to their heterogeneity at presentation and
in their natural history, in the past MDS were
given various names, e.g. smoldering acute
leukemia, preleukemic anemia, refractory ane-
mia, refractory anemia with excess of myelo-
blasts, etc.21,22 In 1982, the French-American-
British (FAB) Cooperative Group categorized
MDS into five morphological subtypes: refracto-
ry anemia (RA), RA with ringed sideroblasts
(RARS), RA with excess of blasts (RAEB), RAEB
in transformation to acute leukemia (RAEB-t)
and chronic myelomonocytic leukemia (CMML),
according to the criteria reported in Table 1.23 Six
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years later, the Morphologic, Immunologic and
Cytogenetic (MIC) Cooperative Study Group
provided additional cytogenetic data that allowed
further refinement.24 Several studies highlighted
that the less aggressive subtypes, RA and RARS,
are extremely rare in children, whereas the
majority of children with MDS fall into the bad
risk categories (RAEB, RAEB-t).25-27 Moreover,
the applicability of the FAB classification to
childhood MDS is not completely satisfactory or
comprehensive of all disorders classically includ-
ed in the group of pediatric myelodys-
plasias.25,26,28,29 In fact, the FAB classification does
not include two of the most common variants of
pediatric MDS described in the literature, name-
ly juvenile chronic myelogenous leukemia
(JCML) and the monosomy 7 syndrome, which
share clinical and biological features found in
both MDS and myeloproliferative disorders
(MPD). Thus, it is clear that some overlap
between MDS and MPD exists and this is partic-
ularly evident in childhood. On the basis of these
considerations, a tentative and arbitrary classifi-
cation of childhood MDS which includes the
peculiar pediatric variants and thus implements
the FAB classification is reported in Table 2.
Juvenile chronic myelogenous leukemia
JCML is considered to be the pediatric equiva-
lent of adult CMML because it shares similar
clinical and biological characteristics, as well as
karyotype abnormalities.18,24,25,28,30 JCML is a rare
hematopoietic malignancy of early childhood
representing less than 2% of all childhood
leukemias.31 A higher incidence of the disease in
males and in patients with type 1 neurofibro-
matosis (NF-1) has been reported. At diagnosis,
most of the patients are under two years of age
and over 90% have not yet reached the age of
four. Patients are often difficult to diagnose
because of their clinical heterogeneity. Spleno-
megaly, hepatomegaly, generalized lymphade-
nopathy and skin manifestations (eczematous
rash, xanthomata) are common clinical features.
Leukemic infiltration of the lungs may deter-
mine a clinical picture characterized by cough,
tachypnea and bronchospasm, with an intersti-
tial radiological pattern.
Leukocytosis (usually under 1003109/L),
monocytosis, anemia, variable normoblastemia
and thrombocytopenia represent the peripheral
blood pattern most frequently reported at the
onset of the disease.30,31 Other laboratory find-
ings include an increased synthesis of hemoglo-
bin F (associated with reversion to fetal hema-
topoiesis), elevated serum levels of murami-
dase, vitamin B12 and serum IgG, IgA and IgM.
The presence of autoantibodies is also com-
mon. Leukocyte alkaline phosphatase cannot be
regarded as a specific marker of the disease
since 60% of patients have a normal or even
increased score.31 The Philadelphia chromo-
some is always absent, even though other chro-
mosomal abnormalities have been reported in
18% of the cases described.31
JCML is characterized by an aggressive clinical
course and, even though patients rarely undergo
transformation to a frank blast crisis, median
survival time is less than 10 months from diag-
nosis.30 Variables demonstrated to be associated
with a shorter survival are: age greater than two
years at presentation, hepatomegaly, bleeding,
thrombocytopenia, high counts of normoblasts
and blast cells in the peripheral blood.30 In par-
ticular, children diagnosed before the age of two
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Table 1. Peripheral blood and bone marrow findings in the myelodysplastic
syndromes.
RA RARS RAEB RAEB-t CMML
Peripheral blood blasts (%) <1 <1 <5 may be >5 <5%
Abnormal marrow blasts (%) <5 <5 5-20 5-30 5-20
Ringed sideroblasts >15% – + ± ± ±
Auer rods – – – ± –
Peripheral blood monocytosis
(> 1 x 109/L) – – – – +
RAEB-t is diagnosed in the presence of i) Auer rods; ii)>5% blasts in the peripheral
blood, or iii) 20-30% of blasts in the bone marrow.
Table 2. Classification of myelodysplastic syndromes in childhood.
Primary myelodysplasia
Refractory anemia (RA)
Refractory anemia with ringed sideroblasts (RARS)
Refractory anemia with excess of blasts (RAEB)
Refractory anemia with excess of blasts in transformation (RAEB-t)
Juvenile chronic myelogenous leukemia (JCML) 
Infantile monosomy 7 syndrome
Secondary myelodysplasia
Therapy-related myelodysplastic syndromes
may have a more indolent course and a pro-
longed survival without intensive treatment. The
response to agents employed for the treatment of
adult type CML (busulfan, hydroxyurea and
interferon-a) is poor32 and even intensive combi-
nation chemotherapy has produced only sup-
pression, but not eradication, of the malignant
clone.33,34 Allogeneic bone marrow transplanta-
tion (BMT) appears to be the only curative strat-
egy for the disease at this time.35 Sanders and col-
leagues35 reported that six out of 14 patients who
received an allogeneic BMT (six from an HLA-
identical sibling and eight from a partially-
matched family donor) have remained in remis-
sion for as long as 11 years after transplantation.
Spontaneous growth of granulocyte-macro-
phage progenitors (CFU-GM) and inhibition of
normal hematopoietic progenitors seems to rep-
resent the main pathogenetic mechanism of
JCML. A number of in vitro studies aimed at
elucidating the biological behavior of hema-
topoietic progenitors from JCML patients have
found that: i) JCML CFU-GM can proliferate in
semisolid cultures in the absence of added
growth factors;36 ii) spontaneous CFU-GM
growth depends on the presence of monocytes-
macrophages since it can be suppressed by
adherent cell depletion;37 iii) the spontaneous
CFU-GM growth is determined by granulocyte-
macrophage colony stimulating factor (GM-
CSF) that acts as an autocrine-paracrine growth
factor;38 iv) CFU-GM growth is attributable to a
striking hypersensitivity of CFU-GM to GM-
CSF and not to cytokine overproduction.39 The
primary pathogenetic mechanism of JCML also
seems to involve the autocrine production and
release of tumor necrosis factor-a (TNF-a). In
fact, TNF-a plays a central role in determining
the inhibition of normal hematopoiesis and
directly determines the proliferation of malig-
nant monocytes-macrophages and GM-CSF
production. This, in turn, further promotes
replication of GM-CSF hypersensitive cells, with
interleukin-1 (IL-1) representing an important
accessory factor that augments the effect of GM-
CSF and TNF-a.40 Recently, we demonstrated
that allogeneic BMT, which leads to the eradica-
tion of the malignant clone and its substitution
with the normal hematopoiesis of the donor,
interrupts the autocrine-paracrine loop of
JCML cell replication and also brings about the
disappearance of the growth-inhibitory effect of
cytokines on normal hematopoiesis.41 The cru-
cial role played by GM-CSF in the pathogenesis
of JCML makes this cytokine and its receptor
attractive therapeutic targets for receptor-specif-
ic monoclonal antibodies or growth factor ana-
logues.
Monosomy 7 syndrome
Monosomy and partial deletion of chromo-
some 7 have been described in primary AML
and MDS and, especially, in secondary or thera-
py-related AML and MDS. All these conditions
are exquisitely characterized by recurrent bacte-
rial infections, attributable to a defect in neu-
trophil chemotaxis.42 However, they also charac-
terizes a distinct variant of hematological malig-
nancy in childhood, the monosomy 7 syn-
drome.43,44 This syndrome most often affects
boys under 2 years of age and its clinical presen-
tation resembles that observed in some myelo-
proliferative disorders, in particular JCML. It
can be distinguished from this latter entity
because patients with the monosomy 7 syn-
drome usually have higher platelet counts, nor-
mal fetal hemoglobin and a greater propensity
to undergo transformation to AML. Familial
forms of monosomy 7 have also been described,
with some subjects carrying the cytogenetic
lesion without any clearly evident clinical or
hematological abnormality.45,46 In the report
published by Shannon and co-workers,46 in 2
out of 3 pairs of siblings with monosomy 7, the
presence of different parental chromosomes 7
invalidated the hypothesis that the Knudson
model of oncogenesis (2 mutational events
affecting tumor suppressor genes) represented
the pathogenetic basis of this abnormality. The
possibilities proposed by the authors that the
loss of the long arm of chromosome 7 is an
incidental finding in MDS, unrelated to the
development and progression of the disease, or
alternatively that chromosome deletions are
necessary for but not sufficient to produce MDS
(thus at least one more genetic lesion would be
required) stimulated intensive research aimed at
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clarifying how deletion of chromosome 7 con-
tributes to leukemogenesis. In this regard, a
recently published report proposed a model in
which chromosome 7 deletions participate in
the development of MDS/MPD by gene
dosage.47 One practical consideration for this
condition is that children with the monosomy 7
syndrome should not receive a marrow trans-
plant from an HLA-identical sibling until it has
been clearly and unequivocally shown that the
potential donor does not present the cytogenet-
ic abnormality.
Cytogenetic and molecular findings in MDS
Cytogenetic analysis of bone marrow cells is
an essential step in the diagnostic process for all
children with suspected or documented  myelo-
dysplasia. Sequential examinations are also
strongly recommended in order to detect possi-
ble clonal evolution which is frequently
encountered during the progression of the dis-
ease. The MIC Cooperative study group
demonstrated that about 60% of patients with
idiopathic MDS and more than 90% of those
affected by secondary myelodysplasia show an
abnormal karyotype.24 The most frequently
detected cytogenetic abnormalities include
monosomy of chromosome 7 (see above), tri-
somy of chromosome 8, monosomy of chro-
mosome 5, deletions of the long arm of chro-
mosome 7 or 5 and, more rarely, abnormalities
involving chromosomes 11, 19, 20 and 21.
Detection of monosomy 7 or complex cytoge-
netic abnormalities have been associated with
poor prognosis, and patients with secondary or
therapy-related MDS are more likely to present
karyotype abnormalities predictive of unfavor-
able outcome. The frequent involvement of
chromosomes 5 and 7 in MDS has suggested
intriguing hypotheses regarding the role of
hematopoietic growth factors and some of their
receptors in the pathogenesis of these disorders.
In fact, the long arm of chromosome 5 contains
genes coding for GM-CSF, interleukin-3 (IL-3),
interleukin-4, interleukin-5, monocyte colony-
stimulating factor (M-CSF) and the c-fms onco-
gene, which codes for the M-CSF receptor,
whereas the genes for erythropoietin, multiple
drug resistance 1, multiple drug resistance 2,
met oncogene and T-cell receptor b and g
chains have been found on the long arm of
chromosome 7.48 The common involvement of
5q or 7q lesions in MDS, together with the con-
centration in these regions of genes involved in
hematopoiesis, is suggestive, although their role
in the development of the preleukemic state has
not been clearly defined. It can be hypothesized
that an abnormal structure or an altered regula-
tion of the expression of these genes, while not
constantly observed in MDS, might play an
essential part in the leukemogenic process by
conferring a proliferative advantage or by pre-
disposing to additional genetic lesions by
increasing genetic instability.49 Nevertheless, it
cannot be excluded that the loss of a normal
allele may unmask a recessive mutant of an
anti-oncogene on the remaining chromosome.
It must be mentioned that several studies have
pointed out the role of mutations of the RAS
gene family (H-RAS, K-RAS and N-RAS, three
21-kD guanine nucleotide-binding proteins
implicated in the control of cellular prolifera-
tion and differentation) in the pathogenesis of
MDS. In the active state RAS is bound to guano-
sine triphosphate (GTP) and transmits signals
from the external milieu of the cell to its interi-
or, whereas RAS becomes inactive when GTP is
hydrolyzed to guanosine diphosphate (GDP).
Mutations in codons 12, 13 and 61 have been
described in about 30-40% of patients with
MDS and these usually determine increased lev-
els of RAS-GTP.49-51 In particular, RAS activation
seems to favor malignant progression through a
selective growth advantage presented by the
cells in which the mutation occurs and through
interference with their genetically established
differentiation program. Identification of mole-
cular lesions at the level of RAS or c-fms onco-
genes can also contribute to documenting MDS
in patients whose clinical and laboratory find-
ings do not permit a certain diagnosis and for
whom the use of X-linked DNA polymorphisms
does not provide useful information.
Shannon et al.52  recently demonstrated that
loss of the normal NF1 allele from the bone
marrow of children with NF1 may predispose
to the development of MDS. In fact, neurofi-
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bromin, encoded by the NF1 gene, is a GTPase-
activating protein that binds to RAS and accel-
erates the hydrolysis of GTP to GDP.53,54 Since
GTPase-activating proteins regulate the process
of signal transduction involving RAS genes, loss
or inactivation of a GTPase-activating protein
such as NF1 could lead to elevated levels of
RAS-GTP and this could represent an essential
step in malignant transformation.52-54 Shannon
et al.52 also documented a loss of heterozygosity
for the NF1 gene in bone marrow samples from
5 out of 11 children with NF1 in whom malig-
nant myeloid disorders developed, thus provid-
ing evidence that the NF1 gene acts as a tumor
suppressor in myeloid cells in vivo. The role of
NF1 in the pathogenesis of MDS in children
who do not have NF1 is still unclear, even
though the same authors analyzed 25 children
with myeloid disorders and monosomy 7 and
found that all bone marrow samples retained
parental alleles.
Treatment strategies for pediatric MDS
Clinical and biological heterogeneity is an
intrinsic characteristic of myelodysplasia; some
subtypes are associated with short survival and
others with a more indolent prolonged course.
Due to the wide variation in survival and
propensity to undergo transformation to AML
(Table 3) among patients belonging to the same
FAB subgroup of MDS, alternative attempts at
assessing prognosis and refining the prognostic
value of the FAB classification have been elabo-
rated.55-57 Prognostic factors reported to be asso-
ciated with short survival include pancytopenia
(particularly anemia and thrombocytopenia),
high peripheral blood and bone marrow blast
counts, abnormal localization of immature pre-
cursors (ALIP) on marrow trephine biopsy,
increased percentage of CD34+ cells in the bone
marrow, karyotype abnormalities (especially
the more complex ones) and RAS oncogene
activation, which seems to play a role in malig-
nant progression to AML (Table 4).55-61
As mentioned above, myelodysplasia in chil-
dren is often characterized by an aggressive
clinical course, the virtual absence of some sub-
groups (i.e. RARS) and by the presence of pecu-
liar variants (i.e. JCML and the monosomy 7
syndrome).26,62 These observations must be held
in due consideration when choosing the opti-
mal therapeutic strategy. Moreover, on the basis
of the longer life expectancy of children as com-
pared to adults, data available on the different
treatment options referring mainly to adult
patients are only partially applicable to the
management of pediatric MDS. In fact, the pri-
mary aim of the pediatric hematologist should
be a definitive cure or at least a durable stabi-
lization of the clinical and hematological situa-
tion of the patient, achievable through the
eradication or alternatively the differentiation
of the malignant clone, leading to a reconstitu-
tion of normal hematopoiesis.
Supportive therapy
Since bleeding and infection are more com-
mon causes of death than progression to AML,
transfusions and antibiotic therapy are still the
mainstay of treatment.
Pyridoxine, folic acid, corticosteroids and
androgens seem to be of little utility in patients
with MDS. In particular, clinical trials on the
use of corticosteroids have shown little efficacy,
with only minor and transient increments in
hemoglobin levels.63 Prolonged therapy with
corticosteroids is associated with an increased
risk of side effects that outweighs their possible
benefits. In randomized trials, androgen therapy
improved neither the hematological picture nor
the overall survival of patients affected by
RAEB-t.64,65
In conclusion, while supportive therapy alone
is a reasonable approach in the elderly, the
Table 3. Prognosis of patients with primary MDS not receiving BMT,
according to FAB subtype.
Category Median survival in months Leukemic progression
(range) (%)
RA 50 (18-64) 12
RARS 51 (14-76+) 8
RAEB 11 (7-16) 44
RAEB-t 5 (2.5-11) 14
CMML 11 (9-60+) 60
Adapted from Rowley M. The myelodysplastic and myeloproliferative syndromes. In:
Treleaven J, Barret J, eds. Bone marrow transplantation in practice. London: Churchill
Livingstone, 1992:49-64.
longer life expectancy, better response to aggres-
sive treatment and superior results of marrow
transplant when performed in the early stages
of MDS should be adequately considered in
younger patients. 
Differentiative treatments
Certain drugs in vitro can induce maturation
of a clone of cells arrested at an earlier stage of
development, and this observation has signifi-
cant relevance in the treatment of MDS. The
most intensively studied agents are 13-cis
retinoic acid, 1,25-dihydroxyvitamin D3, a-
interferon and low-dose cytosine arabinoside
(Ara-C). Encouraging results were reported in
the first pilot studies of 13-cis retinoic acid in
myelodysplasia, but two subsequent randomized
trials failed to confirm its efficacy.66,67 Likewise,
the use of 1,25-dihydroxyvitamin D3 did not
modify the clinical course of the disease.68 
Low-dose Ara-C causes significant cytopenia
in patients with myelodysplasia, probably
because it acts as a chemotherapeutic agent
rather than a differentiating drug. In two pub-
lished studies a considerable proportion of
treated patients presented a partial or complete
response, even though this effect was obtained
at the cost of an increased incidence of infec-
tious complications and toxic death.69,70 Low-
dose Ara-C failed to demonstrate clinical bene-
fit when compared to supportive therapy in an
intergroup study.71
Therapy with low-dose etoposide (VP-16), a
drug with differentiative capacity on human
leukemic cell lines at low concentrations in
vitro, has recently been shown to be valuable in
inducing partial or complete hematological
response in patients with MDS.72 Three mecha-
nisms were hypothesized by the authors to
explain the effects of VP-16: i) its cytotoxic
effect; ii) its ability to cause differentiation of
malignant cells, and iii) prolongation of blood
cell survival by destruction of the reticuloen-
dothelial system. Nevertheless, these prelimi-
nary results must be confirmed in larger, ran-
domized clinical trials before VP-16 can be con-
sidered an attractive alternative option for
patients without an HLA-identical donor and
those with a stable clone.
High-dose chemotherapy
The observation that most pediatric MDS are
characterized by an extremely aggressive clinical
course6,25-27 has justified the use of intensive treat-
ment aimed at eradicating the malignant clone
and reconstituting normal hematopoiesis.73
Chemotherapy has been found to induce hema-
tological remission in a percentage of young
patients similar to that observed in cases of pri-
mary AML.74-76 However, the response to chemo-
therapeutic agents is limited and complicated by
prolonged periods of aplasia, and the duration
of remission has generally been short. 
Autologous BMT, theoretically questionable
in a disorder involving the multipotent hema-
topoietic stem cell, was recently proposed by
the Childrens Cancer Group77 after a condition-
ing regimen consisting of busulfan and cyclo-
phosphamide. In this trial, which included
patients with both AML and MDS, children
lacking an HLA-identical sibling received inten-
sively timed induction therapy followed by 4-
hydroperoxycyclophosphamide-purged autolo-
gous marrow transplantation. The reported
results are encouraging, but they should be
considered preliminary and need to be con-
firmed in a larger randomized study able to dis-
tinguish the role of the intensively timed induc-
tion therapy from the role played by the mye-
loablative doses of chemotherapy used for
autologous BMT.
Busulfan and hydroxyurea with or without
splenectomy, while effective in Philadelphia
chromosome-positive chronic myelogenous
leukemia (CML), have not proved to be particu-
larly effective in children with JCML. On the
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Table 4. Factors influencing the natural history of patients with MDS.
Percentage of peripheral blood blasts
Percentage of bone marrow blasts
Number of hematopoietic lines involved 
Severity of cytopenia
Abnormal localization of immature precursors (ALIP)
Percentage of CD34+ cells
Presence of karyotype abnormalities
Mutations of RAS proto-oncogenes
Secondary myelodysplasia
contrary, these patients are reported to benefit
from treatment with oral 6-mercaptopurine
alone or in combination with subcutaneous
Ara-C.78,79 Nonetheless, Castro-Malaspina et al.30
found that none out of 33 patients affected by
JCML and given chemotherapy achieved com-
plete remission.
There is no widely accepted agreement on the
treatment for the infantile monosomy 7 syn-
drome. Two out of 6 children with this syn-
drome given combination chemotherapy were
reported to be in remission 4 and 5 years,
respectively, after the end of treatment.80
Hematopoietic growth factors
The hematopoietic growth factors most com-
monly used in clinical trials on patients with
myelodysplasia are GM-CSF, granulocyte
colony-stimulating factor (G-CSF) and recom-
binant human erythropoietin (rHuEPO). He-
matopoietic growth factors are employed in an
attempt to reverse the defective proliferation
and differentiation of hematopoietic precursors
within the MDS marrow and, consequently, to
modify the dominant cytopenias with their
related morbidities. Both GM-CSF and G-CSF
have proven to be effective in increasing granu-
locyte production in 75-90% of neutropenic
patients, even though no study specifically
addressed treatment of pediatric MDS.81-86
Studies on the clonality of hematopoiesis after
treatment with cytokines suggest that GM-CSF
and G-CSF do not preferentially stimulate nor-
mal hematopoiesis, but rather induce differenti-
ation of the abnormal clone without having the
capacity to eradicate the clone itself.86,87 G-CSF
and GM-CSF therapy can also contribute to the
resolution of infections in those patients who
experience a substantial increase in their neu-
trophil count. GM-CSF and G-CSF did not
improve platelet and reticulocyte production in
the reported trials of MDS patients. 
Concern about possible risks inherent in stim-
ulating the proliferation of leukemic cells and
the consequent evolution of myelodysplasia to
AML was raised in an early study of GM-CSF.84
However, since an increase in blasts is part of
the natural history of MDS, no firm conclusion
can be drawn about the impact of cytokine ther-
apy on transformation to acute leukemia.
The long-term effects of both GM-CSF and
G-CSF on the natural history and survival of
MDS patients remain to be established, and
randomized controlled studies are awaited to
determine whether colony stimulating factors
can really ameliorate the duration and/or the
quality of life of patients with myelodysplasia.
In some patients with MDS, serum erythro-
poietin levels are lower than would be expected
relative to the degree of anemia;88 this observa-
tion has led to trials investigating the use of
rHuEpo to correct the hyporegenerative ane-
mia. Several studies have been published and it
can be concluded that no more than 10-25% of
myelodysplastic patients benefit from treatment
with rHuEpo.89-91
Recent studies have demonstrated in vitro
synergy between G-CSF and rHuEpo for nor-
mal and MDS erythropoiesis.92,93 Leary et al.94
showed that G-CSF enhanced the development
of early precursors into erythropoietin-respon-
sive progenitors cells. A clinical trial document-
ed a synergistic in vivo effect of G-CSF and
rHuEpo on the anemia of patients with myelo-
dysplasia, with a substantial percentage of sub-
jects presenting both erythroid and myeloid
improvement.95 Responses were more frequent
in patients with less advanced pancytopenia
and lower endogenous erythropoietin levels,
but the durability of these increases must still
be clearly assessed.
IL-3 has been shown to be effective in
increasing granulocyte, reticulocyte and platelet
production in about 50% of MDS patients.
However, the improvement in neutrophil count
was not as significant as that observed after
treatment with G-CSF or GM-CSF, and the
effects on the other cell lines were likewise lim-
ited.96 The therapeutic role of IL-3 in associa-
tion with other hematopoietic growth factors,
as well as the efficacy of the c-kit ligand have yet
to be clarified definitively.
Allogeneic bone marrow transplantation
Considering that children with MDS have a
high risk of death due to cytopenia or clonal
evolution to AML and that conventional
chemotherapy has not proven effective, those
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with an HLA-histocompatible sibling should be
considered elective candidates for allogeneic
BMT. Allogeneic marrow transplantation repre-
sents the only curative treatment for myelo-
dysplasia in young patients at present, and
reports have emphasized that a significant per-
centage of these patients can be cured with
marrow transplant.97-103
In the study reported by DeWitte et al. for
the European Bone Marrow Transplant
Group,98  disease-free survival was about 50%
and the best results were observed in patients
affected by MDS with low proliferative capaci-
ty, i.e. RA and some cases of RAEB, and in
patients with a more advanced stage of disease
but in complete hematological remission at the
time of transplant.
In the largest and most recent update of the
Seattle data101 involving 93 patients treated for
MDS with an allogeneic BMT from HLA-identi-
cal siblings or partially-matched family donors,
the probability of disease-free survival, relapse,
and non-relapse mortality at 4 years was 41%,
28% and 43%, respectively. Young age (under
40), absence of an excess of blasts, and short
disease duration were found to be good prog-
nostic factors.
Although a few pediatric cases were included
in some of the previously published studies,
there are only two reports specifically address-
ing the question of BMT in children with MDS.
In the first study published by Guinan et al.99 in
1988, eight children with MDS were transplant-
ed with an HLA-identical sibling after a condi-
tioning regimen consisting of fractionated total
body irradiation (TBI) and chemotherapy.
Both the drugs employed and the doses of
radiotherapy delivered differed among the
patients, and GVHD prophylaxis was heteroge-
neous. There were no relapses and four out of
the eight children became long-term disease-
free survivors; four patients died of rejection
and acute or chronic GVHD.
Recently, we reported on eight children with
MDS who received allogeneic BMT with homo-
geneous myeloablative therapy and GVHD pro-
phylaxis.104 Myeloablative therapy consisted of
the classic little busulfan-cyclophosphamide (BU,
Cy) regimen proposed by Tutschka et al.105 to
which melphalan (L-PAM) was added, since we
speculated that by adding this drug the killing of
malignant cells could be further increased.
Moreover, a conditioning regimen consisting of
three alkylating drugs with non-cell-cycle-active
action appears to be potentially capable of erad-
icating stem cell disorders in which at least a
portion of the clonogenic cells are dormant out
of cycle. This conditioning regimen was well tol-
erated. Only one patient died of transplant-
related interstitial pneumonia of unclear etiolo-
gy and another with RAEB-t and monosomy 7
relapsed 11 months after BMT, whereas the
other 6 children became disease-free survivors.
The three children affected by JCML obtained a
complete remission and are now alive and dis-
ease free. 
Our experience with patients having this vari-
ant of MDS, which represents, albeit with some
distinctive features, the pediatric counterpart of
adult CMML compares favorably  with that of
the Seattle Group mentioned above,35 in which
three of six children given a transplant from an
HLA-identical sibling and three of eight receiv-
ing a partially-matched graft after a TBI-con-
taining regimen are alive and in hematological
remission. Our data seem to suggest that a con-
ditioning regimen consisting of BU, Cy and L-
PAM is sufficient to permit achievement of
remission in JCML and probably to eradicate
the single genetically altered clone that domi-
nates blood cell production. Since there have
been several reports about the long-term mor-
bidity of TBI,106-108 avoiding radiotherapy in the
conditioning regimen would also have the
advantage of reducing the risk of radiation-
induced severe growth retardation, endocrine
disorders, cataract development and neuropsy-
chological sequelae.
Data on mismatched family and unrelated
donor transplant for patients with MDS are still
not conclusive. Some authors101 report encour-
aging results after BMT using a partially-
matched family donor, whereas Kernan et al.109
found 18% 2-year actuarial disease-free sur-
vival for 32 patients given unrelated-donor
transplant, with the donors being supplied
through the National Marrow Donor Program.
Therefore, at present, BMT with mismatched
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family and unrelated donors should not be con-
sidered routine therapy, but should be evaluat-
ed in the context of clinical trials that weigh the
biological and clinical features together with
the relative prognostic implications of each
individual patient.
Conclusions
Myelodysplasia in childhood usually runs an
aggressive course with a great proportion of
patients succumbing in the first 1-2 years after
diagnosis. Available evidence indicates that
BMT currently represents the only curative
strategy for myelodysplastic children. 
Therefore, on the basis of the reduced trans-
plant-related mortality and morbidity in child-
hood and the better results achievable in
patients with less advanced disease, children
with all different variants of MDS and a suitable
HLA-identical donor should be offered allo-
geneic marrow transplantation as early as possi-
ble in the course of the disease.
In children without an HLA-identical sibling
and those having MDS variants associated with
poorer prognosis (JCML, monosomy 7 syn-
drome, RAEB and RAEB-t), the possibility of
using donors other than HLA-matched siblings
could increase the applicability of BMT. For
patients with a stable clone and low prolifera-
tive capacity MDS (i.e. RA), clonal manipula-
tion to overcome abnormalities in cellular mat-
uration, with consequent amelioration of cyto-
penia, and to eliminate more malignant sub-
clones could represent an attractive alternative,
especially if our knowledge of the cellular dif-
ferentiation pathways improves.
In the future, pediatric hematologists should
pay more attention to childhood myelodysplasia
in order to better define the biological, clinical,
therapeutic and prognostic implications of the
pediatric variants of MDS. The peculiar pedi-
atric variants in particular should be studied in
order to arrive at a more widely accepted classi-
fication that will permit prognostic and thera-
peutic comparisons. Moreover, fundamental
information deriving from these investigations
could provide insights into other hematologi-
cal/oncological disorders as well.
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